| 2022-07-21 |
复牌提示：
2022-07-21 07:56:22 停牌，复牌日期 2022-07-22 00:00:01
|
| 2022-06-02 |
股东大会：
将于2022-07-06召开股东大会
会议内容 ▼▲
- 1.To consider and vote on the proposal to adopt the Agreement and Plan of Merger, made and entered into as of April 17, 2022 (as amended from time to time, the “Merger Agreement”), by and among Natus, Prince Parent Inc. (“Parent”), and Prince Mergerco Inc. (“Merger Sub”). Each of Parent and Merger Sub is affiliated with an investor group comprised of funds managed by ArchiMed, an investment firm focused on the healthcare industry. Pursuant to the terms of the Merger Agreement, Merger Sub will be merged with and into Natus and Natus will continue as the surviving corporation of the Merger and a wholly owned subsidiary of Parent (the “Merger”);
2.To consider and vote on the proposal to adjourn the Company Stockholder Meeting from time to time, if necessary or appropriate, as determined in good faith by the Board of Directors, including to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the Company Stockholder Meeting;
3.To consider and vote on the proposal to approve, by non-binding, advisory vote, certain compensation that will or may become payable by Natus to its named executive officers in connection with the Merger.
|
| 2022-06-02 |
详情>>
股本变动：
变动后总股本3458.29万股
|
| 2022-05-06 |
详情>>
业绩披露：
2022年一季报每股收益0.06美元,归母净利润190.30万美元,同比去年增长-20.58%
|
| 2022-05-05 |
财报披露：
美东时间 2022-05-05 盘后发布财报
|
| 2022-04-28 |
股东大会：
将于2022-06-15召开股东大会
会议内容 ▼▲
- 1.Election of seven director nominees named in the attached Proxy Statement to serve until either the 2023 annual meeting or until their respective successors are duly elected and qualified.
2.Approval of the Amended and Restated 2011 Employee Stock Purchase Plan.
3.Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement.
4.Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
|
| 2022-02-25 |
详情>>
业绩披露：
2019年年报每股收益-0.47美元,归母净利润-1567.1万美元,同比去年增长31.67%
|
| 2022-02-25 |
详情>>
业绩披露：
2021年年报每股收益0.39美元,归母净利润1317.70万美元,同比去年增长179.32%
|
| 2021-11-05 |
详情>>
业绩披露：
2021年三季报(累计)每股收益0.34美元,归母净利润1143.30万美元,同比去年增长152.41%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-06 |
详情>>
业绩披露：
2021年中报每股收益0.17美元,归母净利润586.00万美元,同比去年增长146.88%
|
| 2021-05-07 |
详情>>
业绩披露：
2021年一季报每股收益0.07美元,归母净利润239.60万美元,同比去年增长166.61%
|
| 2021-04-28 |
股东大会：
将于2021-06-16召开股东大会
会议内容 ▼▲
- 1.Election of seven director nominees named in the attached Proxy Statement to serve until either the 2022 annual meeting or until their respective successors are duly elected and qualified.
2.Approval of the 2021 Equity Incentive Plan.
3.Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement.
4.Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
|
| 2021-02-26 |
详情>>
业绩披露：
2020年年报每股收益-0.49美元,归母净利润-1661.3万美元,同比去年增长-6.01%
|
| 2021-02-26 |
详情>>
业绩披露：
2018年年报每股收益-0.69美元,归母净利润-2293.5万美元,同比去年增长-13.02%
|
| 2020-11-04 |
详情>>
业绩披露：
2020年三季报(累计)每股收益-0.65美元,归母净利润-2181.6万美元,同比去年增长-16.78%
|
| 2020-08-04 |
详情>>
业绩披露：
2020年中报每股收益-0.37美元,归母净利润-1250万美元,同比去年增长53.55%
|
| 2020-05-08 |
股东大会：
将于2020-06-17召开股东大会
会议内容 ▼▲
- 1.Election of five director nominees named in the attached Proxy Statement to serve until either the 2021 annual meeting or until their respective successors are duly elected and qualified.
2.Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement.
3.Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.
4.And any other business that properly comes before the meeting or any adjournment or postponement thereof by or at the direction of the Board of Directors.
|
| 2020-05-06 |
详情>>
业绩披露：
2020年一季报每股收益-0.11美元,归母净利润-359.7万美元,同比去年增长88.17%
|
| 2019-04-15 |
股东大会：
将于2019-06-05召开股东大会
会议内容 ▼▲
- 1.Amendment to our Restated Certificate of Incorporation to declassify the Board of Directors.
2.Amendment to our Restated Certificate of Incorporation to eliminate cumulative voting.
3.Election of three director nominees named in the attached Proxy Statement to serve until either the 2022 annual meeting (if Proposal 1 is not adopted) or the 2020 annual meeting (if Proposal 1 is adopted) and, in either case, until their respective successors are duly elected and qualified.
4.Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement.
5.Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.
|
| 2018-11-09 |
股东大会：
将于2018-12-13召开股东大会
会议内容 ▼▲
- 1.To approve the 2018 Equity Incentive Plan (the “2018 Plan”).
|
| 2017-04-28 |
股东大会：
将于2017-06-21召开股东大会
会议内容 ▼▲
- 1.To elect two directors to serve for a term of three years;
2.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2017;
3.Advisory approval of the Company’s named executive officer compensation;
4.Advisory approval of the frequency of stockholders’ say-on-pay vote on named executive officer compensation;
5.Transaction of such other business as may properly come before the meeting or any adjournment thereof.
|
| 2016-04-22 |
股东大会：
将于2016-06-02召开股东大会
会议内容 ▼▲
- 1.To elect two directors to serve for a term of three years;
2.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2016;
3.Advisory approval of the Company’s named executive officer compensation
4.Transaction of such other business as may properly come before the meeting or any adjournment thereof.
|
| 2015-04-24 |
股东大会：
将于2015-06-04召开股东大会
会议内容 ▼▲
- 1.To elect two directors to serve for a term of three years;
2.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2015;
3.Advisory approval of the Company’s named executive officer compensation;
4.To approve the Natus Medical Incorporated Cash Incentive Plan;
5.Transaction of such other business as may properly come before the meeting or any adjournment thereof.
|
| 2015-01-02 |
详情>>
内部人交易：
CHUNG DONG CHUNE CHRISTOPHER等共交易5笔
|
| 2014-04-21 |
股东大会：
将于2014-06-06召开股东大会
会议内容 ▼▲
- 1. To elect a director to serve for a term of three years;
2. To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2014;
3. To approve an amendment to the Company’s 2011 Stock Awards Plan;
4. Advisory approval of the Company’s Named Executive Officer compensation;
5. Transaction of such other business as may properly come before the meeting or any adjournment thereof.
|
| 2013-04-19 |
股东大会：
将于2013-06-07召开股东大会
会议内容 ▼▲
- 1. To elect two directors to serve for a term of three years;
2. To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2013;
3. Advisory approval of the Company’s Named Executive Officer compensation;
4. Transaction of such other business as may properly come before the meeting or any adjournment thereof.
|